Authors: GOLDHIRSCH A GELBER RD PRICE KN CASTIGLIONE M COATES AS RUDENSTAM CM COLLINS J LINDTNER J HACKING A MARINI G BYRNE M CORTESFUNES H SCHNURCH G BRUNNER KW TATTERSALL MHN FORBES J SENN HJ

Citation: A. Goldhirsch et al., EFFECT OF SYSTEMIC ADJUVANT TREATMENT ON FIRST SITES OF BREAST-CANCERRELAPSE, Lancet, 343(8894), 1994, pp. 377-381

Authors: BRUNNER KW

Citation: Kw. Brunner, PRIMUM NIL NOCERE AND CLINICAL CANCER-RES EARCH - THOUGHTS ON A CONTROVERSY, Schweizerische medizinische Wochenschrift, 124(43), 1994, pp. 1885-1886

Authors: GOLDHIRSCH A GELBER RD CASTIGLIONE M PRICE KN RUDENSTAM CM LINDTNER J COLLINS J SENN HJ BRUNNER KW GALLIGIONI E CAVALLI F GUDGEON A CORTESFUNES H TATTERSALL M MARINI G BYRNE M SNYDER R FORBES JF HURNY C COATES A

Citation: A. Goldhirsch et al., PRESENT AND FUTURE PROJECTS OF THE INTERNATIONAL BREAST-CANCER STUDY-GROUP, Cancer, 74(3), 1994, pp. 1139-1149

Authors: BUSER KS JOSS RA PIQUET D AAPRO MS CAVALLI F HAEFLIGER JM JUNGI WF BAUER J OBRIST R BRUNNER KW WEBER T VERITY L BUTCHER M

Citation: Ks. Buser et al., ORAL ONDANSETRON IN THE PROPHYLAXIS OF NAUSEA AND VOMITING INDUCED BYCYCLOPHOSPHAMIDE, METHOTREXATE AND 5-FLUOROURACIL (CMF) IN WOMEN WITHBREAST-CANCER - RESULTS OF A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, Annals of oncology, 4(6), 1993, pp. 475-479

Authors: BORNER MM KNEER J CREVOISIER C BRUNNER KW CERNY T

Citation: Mm. Borner et al., BIOAVAILABILITY AND FEASIBILITY OF SUBCUTANEOUS 5-FLUOROURACIL, British Journal of Cancer, 68(3), 1993, pp. 537-539